Evidence map›Paper›PMID 33954107›Full record

ArticleFrontiers in oncology2021

Knock-Down of Mucolipin 1 Channel Promotes Tumor Progression and Invasion in Human Glioblastoma Cell Lines.

Giorgio Santoni, Consuelo Amantini, Massimo Nabissi, Federica Maggi, Antonietta Arcella, Oliviero Marinelli, Anna Maria Eleuteri, Matteo Santoni, Maria Beatrice Morelli

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Highly Potent and Selective Dopamine DJournal of medicinal chemistry · 2022
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Giorgio SantoniImmunopathology Laboratory, School of Pharmacy, University of Camerino, Camerino, Italy.
Consuelo AmantiniImmunopathology Laboratory, School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.
Massimo NabissiImmunopathology Laboratory, School of Pharmacy, University of Camerino, Camerino, Italy.
Federica MaggiDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
Antonietta ArcellaNeuropathology Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy.
Oliviero MarinelliImmunopathology Laboratory, School of Pharmacy, University of Camerino, Camerino, Italy.
Anna Maria EleuteriClinical Biochemistry Laboratory, School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.
Matteo SantoniMedical Oncology Unit, Hospital of Macerata, Macerata, Italy.
Maria Beatrice MorelliImmunopathology Laboratory, School of Pharmacy, University of Camerino, Camerino, Italy.
Università di Camerino · ITIstituto Neurologico Mediterraneo · ITSapienza University of Rome · ITUniversity of Macerata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among cancers that affect the central nervous system, glioblastoma is the most common. Given the negative prognostic significance of transient receptor potential mucolipin 1 (TRPML1) channel reduction in patients with glioblastoma, as discussed in previous publications, the aim of the current study was to investigate the biological advantage of TRPML1 loss for glioma cells. Human glioblastoma primary cancer cells (FSL and FCL) and glioblastoma cell lines (T98 and U251) were used for that purpose. TRPML1 silencing in T98 cells induces defective autophagy, nitric oxide (NO) production, and cathepsin B-dependent apoptosis in the first 48 h and then apoptotic-resistant cells proliferate with a high growth rate with respect to control cells. In U251 cells, knock-down of TRPML1 stimulates NO generation and protein oxidation, arrests cell cycle at G2/M phase, and induces autophagy leading to cathepsin B-dependent senescence. Finally, in both cell lines, the long-term effects of TRPML1 silencing promote survival and invasion capacity with respect to control cells. Silencing of TRPML1 also affects the phenotype of glioblastoma primary cells. FSL cells show increased proliferation ability, while FCL cells enter into senescence associated with an increased invasion ability. In conclusion, although the molecular heterogeneity among different glioblastoma cell lines mirrors the intercellular heterogeneity in cancer cells, our data support TRPML1 downregulation as a negative prognostic factor in glioblastoma.

Indexed as

apoptosisautophagycathepsin BinvasionmucolipinproliferationsenescenceTRPML1

Identifiers

PMID33954107
PMCPMC8092188
OpenAlexW3153247234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.